Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis

Lucia Masarova, Ahmad Alhuraiji, Prithviraj Bose, Naval Daver, Naveen Pemmaraju, Jorge Cortes, Sherry Pierce, Hagop Kantarjian, Srdan Verstovsek

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


Severe thrombocytopenia (platelets <50 × 109/L) is associated with very poor outcome of patients with myelofibrosis (MF). As patients with primary myelofibrosis (PMF) differ from patients with postessential thrombocythemia (PET-MF) and postpolycythemia vera myelofibrosis (PPV-MF), we aimed to evaluate the significance of low platelets among these patients. We present clinical characteristics and outcome of patients with either PMF, PPV-MF, or PET-MF, and thrombocytopenia who presented to our institution between 1984 and 2015. Of 1269 patients (877 PMF, 212 PPV-MF, 180 PET-MF), 11% and 14% had platelets either <50 × 109/L or between 50-100 × 109/L, respectively. Patients with platelets <50 × 109/L were most anemic and transfusion dependent, had highest blast count and unfavorable karyotype. In general, their overall and leukemia-free survival was the shortest with median time of 15 and 13 months, respectively; with incidence of acute leukemia almost twice as high as in the remaining patients (6.9 vs 3.6 cases per 100 person-years). Nevertheless, this observation remains mostly significant for patients with PMF, as those with PEV/PVT-MF have already significantly inferior prognosis with platelets <100 × 109/L.

Original languageEnglish (US)
Pages (from-to)257-263
Number of pages7
JournalEuropean Journal of Haematology
Issue number3
StatePublished - Mar 2018
Externally publishedYes


  • outcome
  • postessential thrombocythemia myelofibrosis
  • postpolycythemia vera myelofibrosis
  • primary myelofibrosis
  • thrombocytopenia

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis'. Together they form a unique fingerprint.

Cite this